Abatacept in the treatment of rheumatoid arthritis | Zendy

Edward M Vital | Zendy; Paul Emery | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Abatacept in the treatment of rheumatoid arthritis

Author(s) -

Edward M Vital,

Paul Emery

Publication year - 2006

Publication title -

therapeutics and clinical risk management

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.719

H-Index - 55

eISSN - 1178-203X

pISSN - 1176-6336

DOI - 10.2147/tcrm.2006.2.4.365

Subject(s) - abatacept , medicine , rheumatoid arthritis , antirheumatic agents , clinical trial , antirheumatic drugs , tumor necrosis factor alpha , arthritis , oncology , immunology , antibody , rituximab

Abatacept (CTLA4-Ig) is a new agent which targets T-cell activation, an event which is thought to be critical to the onset and maintenance of rheumatoid arthritis (RA). Abatacept now has substantial evidence from phase III trials for efficacy in patients with RA who have failed to respond to disease-modifying antirheumatic drugs (DMARDs) and antitumor necrosis factor-alpha (TNF-alpha) biologic agents. Safety profile is favorable in combination with DMARDs. The mechanism of action and available evidence of its efficacy and safety are reviewed in this article.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research